




ELSEVIER

Contents lists available at ScienceDirect

## Journal of Affective Disorders

journal homepage: [www.elsevier.com/locate/jad](http://www.elsevier.com/locate/jad)

## Corrigendum

Corrigendum to “Can personalized treatment prediction improve the outcomes, compared with the group average approach, in a randomized trial? Developing and validating a multivariable prediction model in a pragmatic megatrial of acute treatment for major depression”. [Journal of Affective Disorders 274 (2020) 690-697]

Toshi A. Furukawa<sup>a,\*</sup>, Thomas P.A. Debray<sup>b</sup>, Tatsuo Akechi<sup>c</sup>, Mitsuhiro Yamada<sup>d</sup>, Tadashi Kato<sup>e</sup>, Michael Seo<sup>f</sup>, Orestis Efthimiou<sup>g</sup>

<sup>a</sup> Departments of Health Promotion and Human Behavior and of Clinical Epidemiology, Kyoto University Graduate School of Medicine / School of Public Health, Kyoto, Japan

<sup>b</sup> Julius Center for Health Sciences and Primary Care, UMC Utrecht, Utrecht University, The Netherlands

<sup>c</sup> Department of Psychiatry and Cognitive-Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan

<sup>d</sup> Department of Neuropsychopharmacology, National Institute of Mental Health, National Center of Neurology and Psychiatry, Tokyo, Japan

<sup>e</sup> Aratama Kokorono Clinic, Nagoya, Japan

<sup>f</sup> Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland

<sup>g</sup> Institute of Social and Preventive Medicine, University of Bern, Switzerland

The authors regret that the format for Table 1 was corrupted. The correct Table 1 appears below. The authors would like to apologise for any inconvenience caused.

DOI of original article: <https://doi.org/10.1016/j.jad.2020.05.141>

\* Correspondence author, at: Departments of Health Promotion and Human Behavior and of Clinical Epidemiology, Kyoto University Graduate School of Medicine / School of Public Health, Yoshida Konoe-cho, Sakyo-ku, Kyoto, Japan.

E-mail addresses: [furukawa@kuhp.kyoto-u.ac.jp](mailto:furukawa@kuhp.kyoto-u.ac.jp) (T.A. Furukawa), [t.debray@umcutrecht.nl](mailto:t.debray@umcutrecht.nl) (T.P.A. Debray), [takechi@med.nagoya-cu.ac.jp](mailto:takechi@med.nagoya-cu.ac.jp) (T. Akechi), [mitsuhiko.yamada@ncnp.go.jp](mailto:mitsuhiro.yamada@ncnp.go.jp) (M. Yamada), [aratama8177@yahoo.co.jp](mailto:aratama8177@yahoo.co.jp) (T. Kato), [swj8874@gmail.com](mailto:swj8874@gmail.com) (M. Seo), [oremiou@gmail.com](mailto:oremiou@gmail.com) (O. Efthimiou).

<https://doi.org/10.1016/j.jad.2020.07.018>

0165-0327/ © 2020 Elsevier B.V. All rights reserved.

Please cite this article as: Toshi A. Furukawa, et al., Journal of Affective Disorders, <https://doi.org/10.1016/j.jad.2020.07.018>

**Table 1**

Baseline socio-demographic and clinical characteristics of the whole sample, as well as the three identified subgroups according to leave-one-patient-out analysis.

	Total sample (n = 1544)	Group 1: Continuing sertraline was the best (n = 123)	Group 2: Combining with mirtazapine was the best (n = 696)	Group 3: Switching to mirtazapine was the best (n = 725)
<b>Socio-demographic characteristics</b>				
Age in years, mean (SD)	41.5 (11.5)	36.1 (8.0)	41.1 (11.0)	42.8 (12.1)
Female sex, n (%)	803 (52%)	87 (70.1%)	260 (37.5%)	394 (54.3%)
Education in years, mean (SD)	14.0 (2.3)	14.2 (2.3)	13.8 (2.2)	14.1 (2.4)
Employment status, n (%)				
Full time	612 (39.6%)	50 (40.7%)	289 (41.5%)	273 (37.7%)
Part-time	133 (8.6%)	1 (0.8%)	72 (10.3%)	60 (8.3%)
On sick leave	427 (27.7%)	56 (45.5%)	176 (25.3%)	195 (26.9%)
Housewife	154 (10.0%)	5 (4.1%)	92 (13.2%)	57 (7.8%)
Student	14 (0.9%)	0 (0.0%)	6 (0.9%)	8 (1.1%)
Retired	15 (1%)	0 (0.0)	2 (0.3%)	13 (1.8%)
Not employed	189 (12.2%)	11 (8.9%)	59 (8.4%)	119 (16.4%)
Marital status, n (%)				
Single (never married)	493 (31.9%)	30 (24.4%)	218 (31.3%)	245 (33.4%)
Divorced	221 (14.3%)	15 (12.2%)	75 (10.8%)	131 (18.1%)
Widowed	32 (2.0%)	0 (0.0%)	19 (2.7%)	13 (1.8%)
Married	798 (51.7%)	78 (63.4%)	384 (55.2%)	336 (46.3%)
<b>Clinical characteristics</b>				
Age (yrs) at onset of first episode, years mean (SD)	36.9 (12.6)	32.5 (9.6)	35.7 (12.0)	38.8 (13.2)
Number of depressive episodes, mean (SD), median, range	2.3 (3.7), median: 1, range: 1-50	1.8 (1.5), median: 1, range: 1-10	2.6 (3.6), median: 2, range: 1-30	2.2 (3.9), median: 1, range: 1-50
Length of current depressive episode (months), mean (SD), median, range	6.3 (15.2), median: 2.5, range: 0.5-276	7.6 (18.3) median: 3.0, range: 0.5-144	6.8 (15.7) median: 3.0, range: 0.5-240	5.6 (14.0) median: 2.0, range: 0.5-276
Comorbid physical illness, n (%)	509 (33.0%)	19 (15.4%)	249 (35.8%)	241 (33.2%)
PHQ-9 total score				
Baseline	18.7 (3.8)	19.6 (3.5)	18.8 (3.9)	18.4 (3.8)
Week 1	15.9 (4.7)	16.9 (4.2)	16.9 (4.7)	14.8 (4.6)
Week 3	12.7 (5.2)	14.9 (5.5)	13.9 (5.2)	11.2 (4.6)
BDI-II total score				
Week 1	28.7 (10.2)	33.8 (9.6)	31.2 (10.0)	25.5 (9.5)
Week 3	24.3 (10.8)	31.7 (11.0)	27.0 (10.6)	20.4 (9.3)
FIBSER total score				
Week 1	6.8 (3.9)	7.9 (3.8)	7.1 (4.1)	6.2 (3.7)
Week 3	7.1 (4.0)	6.0 (3.6)	8.1 (4.3)	6.3 (3.6)
Adherence				
Week 1	6.1 (1.4)	6.1 (1.4)	6.0 (1.4)	6.1 (1.3)
Week 3	6.6 (1.0)	6.5 (1.1)	6.6 (0.9)	6.6 (1.1)

CI: confidence interval. SD: standard deviation.

BDI-II: Beck Depression Inventory, 2<sup>nd</sup> edition. FIBSER: Frequency, Intensity and Burden of Side Effects Rating. PHQ-9: Patient Health Questionnaire-9.